BioMed Research International / 2015 / Article / Tab 1

Research Article

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment

Table 1

Characteristics of patients with late-onset versus adult-onset MS, British Columbia, Canada [aim 1].

CharacteristicsLate-onset MS ()Adult-onset MS () value

Sex, (%)
 Male132 (36.9)1550 (27.5)<0.
 Female226 (63.1)4077 (72.5)
Age at onset, mean (±SD), median [range], years55.4 (4.9), 54.1 [50.0–75.8]32.0 (8.0), 31.2 [18.0–49.99]<0
(%)50–<55 yrs: 201 (56.1)18–<30 yrs: 2539 (45.1)
55–<60 yrs: 104 (29.1)30–<40 yrs: 2013 (35.8)
≥60 yrs: 53 (14.8)40–<50 yrs: 1074 (19.1)
Onset symptoms, (%)
 Motor
  Present140 (39.1)1042 (18.5)<0.
  Absent218 (60.9)4585 (81.5)
 Sensory
  Present107 (29.9)2564 (45.6)<0.
  Absent251 (70.1)3063 (54.4)
 Optic neuropathy
  Present20 (5.6)949 (16.9)<0.
  Absent338 (94.4)4678 (83.1)
 Cerebellar, ataxia, or brainstem
  Present71 (19.8)849 (15.1)0.
  Absent287 (80.2)4778 (84.9)
Initial course, (%)
 Relapsing206 (57.5)5167 (91.8)<0
 Primary-progressive152 (42.5)460 (8.2)
Age at first , mean (±SD), median [range], years 60.5 (6.4), 59.5 [50.4–81.0]41.1 (10.3), 40.7 [18.4–80.9]<0.
Disease duration at first , mean (±SD), median [range], years5.2 (4.7), 3.7 [0.03–30.0]9.1 (8.9), 6.2 [0.0–59.2]<0.
Disease duration at last , mean (±SD), median [range], years 10.2 (5.7), 9.7 [0.3–30.3]16.9 (10.4), 15.1 [0.00–60.2]<0.
Length of prospective follow-up , mean (±SD), median [range], years 5.0 (4.2), 4.1 [0–19.3]7.8 (6.5), 6.4 [0–28.4]<0.
Annualized relapse rate during the first five years after onset of symptoms, mean (±SD), median [range]0.2 (0.3), 0.2 [0–1.8]0.3 (0.4), 0.2 [0–3.2]0.
Year of registration with the clinic, (%)
 1980–198551 (14.2)979 (17.4)0.
 1986–199046 (12.8)799 (14.2)
 1991–199563 (17.6)992 (17.6)
 1996–2000103 (28.8)1568 (27.9)
 2001–200495 (26.5)1289 (22.9)
Exposure to a “disease modifying drug” for MS, (%)
 Ever70 (19.6)2143 (38.1)<0.
 Never288 (80.4)3484 (61.9)
Exposure to a “disease modifying drug” for MS among patients with a relapsing-onset course only, (%)
 Ever63 (30.6)2120 (41.0)0.
 Never143 (69.4)3047 (59.0)
Initially prescribed drug among patients with a relapsing-onset
course only, (%)
 Interferon beta-1a (intramuscular)4 (6.3)274 (12.9)
 Interferon beta-1a (subcutaneous)22 (34.9)731 (34.5)
 Interferon beta-1b (subcutaneous)24 (38.1)755 (35.6)
 Glatiramer acetate11 (17.5)254 (12.0)
 Natalizumab0 (0)9 (0.004)
 Mitoxantrone1 (1.6)43 (2.0)
 Other1 (1.6)54 (2.5)

EDSS, Expanded Disability Status Scale.
Missing for 56 patients with adult-onset MS.
Time from first clinic visit to most recent clinic visit.
Only reported for patients with relapsing-onset MS with at least 5 years of follow-up after the onset of symptoms including 4578 patients with adult-onset MS and 163 with late-onset MS.
Others included clinical trial drugs and cytotoxic immunosuppressants: teriflunomide (both cohorts) and in the adult-onset cohort, methotrexate, azathioprine, cyclophosphamide, FTY720 (fingolimod), cladribine, Hu23F2G (rovelizumab), lenercept, MBP8298 (dirucotide), NBI-5788, paclitaxel, and interferon alpha.
Pearson’s chi-square test.
Student’s -test.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.